<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02633761</url>
  </required_header>
  <id_info>
    <org_study_id>1019</org_study_id>
    <nct_id>NCT02633761</nct_id>
  </id_info>
  <brief_title>Mifepristone-misoprostol vs. Misoprostol Alone for Second Trimester Fetal Death</brief_title>
  <official_title>Mifepristone and Misoprostol Versus Misoprostol Alone for Treatment of Fetal Death at 14-28 Weeks of Pregnancy: A Randomized, Placebo-controlled Double-blinded Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gynuity Health Projects</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gynuity Health Projects</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of this trial is to compare the efficacy of mifepristone-misoprostol versus
      misoprostol alone for treatment of intrauterine fetal demise between 14 and 28 weeks LMP.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary aim of this trial is to compare the efficacy of mifepristone-misoprostol versus
      misoprostol alone for treatment of intrauterine fetal demise between 14 and 28 weeks LMP.
      This will be a randomized controlled double-blinded trial of 150 women comparing misoprostol
      alone to mifepristone plus misoprostol for evacuation of the uterus after fetal demise in the
      second and third trimester. All women in the trial will undergo routine screening and
      pre-medical induction care per standard practice at the hospital.

      All eligible women agreeing to participate in the study will be randomized to receive one of
      the following regimens:

        1. STUDY GROUP ONE: 200mg mifepristone followed in 24 hours by repeated doses of 200mcg
           buccal misoprostol given every 3 hours;

        2. STUDY GROUP TWO: placebo followed in 24 hours by 200mcg buccal misoprostol given every
           three hours.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete uterine evacuation of the fetus and placenta without surgical intervention</measure>
    <time_frame>48 hours</time_frame>
    <description>Complete uterine evacuation of fetus and placenta using study drug alone without recourse to any additional surgical intervention</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Fetal Death</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>200mg mifepristone followed in 24 hours by repeated doses of 200mcg buccal misoprostol given every 3 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo followed in 24 hours by 200mcg buccal misoprostol given every three hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mifepristone</intervention_name>
    <description>200mg mifepristone followed in 24 hours by 200mcg buccal misoprostol every 3 hours.</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo followed in 24 hours by 200mcg buccal misoprostol every 3 hours.</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol 200mcg</intervention_name>
    <description>Buccal misoprostol 200mcg</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Demised fetus of between 14 to 28 weeks duration confirmed by ultrasound

          -  Have no contraindications to study procedure, according to provider

          -  Be able to consent to procedure, either by reading consent document or by having
             consent document read to her

          -  Be willing to follow study procedures.

        Exclusion Criteria:

          -  Allergies or other contraindications to the use of mifepristone or misoprostol;

          -  Placental abruption with active hemorrhage,

          -  Complete placenta previa, extreme uterine structural anomalies, or other
             contradictions to vaginal delivery of the fetus;

          -  Presentation in active labor (moderate to severe contractions every 10 minutes or
             less);

          -  Transmural uterine scars;

          -  Four or more previous deliveries.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hillary Bracken, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gynuity Health Projects</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hillary Bracken, PhD</last_name>
    <phone>2124481230</phone>
    <email>hbracken@gynuity.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital General &quot;Enrique Cabrera&quot;</name>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricio R. Sanhueza-Smith</last_name>
    </contact>
    <contact_backup>
      <last_name>Jose A. Ortiz-Uribe</last_name>
    </contact_backup>
    <investigator>
      <last_name>Patricio R. Sanhueza-Smith</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose A. Ortiz-Uribe</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Institute of Perinatology (INPer)</name>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rodrigo Zamora-Escudero</last_name>
    </contact>
    <contact_backup>
      <last_name>Marco A. Ortiz-Ramirez</last_name>
    </contact_backup>
    <investigator>
      <last_name>Rodrigo Zamora-Escudero</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marco A. Ortiz-Ramirez</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Ob-Gyn Hospital</name>
      <address>
        <city>Hanoi</city>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nguyen thi Hong Minh, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nguyen thi Hong Minh, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 8, 2015</study_first_submitted>
  <study_first_submitted_qc>December 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2015</study_first_posted>
  <last_update_submitted>July 15, 2016</last_update_submitted>
  <last_update_submitted_qc>July 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fetal death</keyword>
  <keyword>mifepristone</keyword>
  <keyword>misoprostol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Death</mesh_term>
    <mesh_term>Fetal Death</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
    <mesh_term>Mifepristone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

